Masashi Wakabayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Masashi Wakabayashi has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
- Genichiro Ishii
Department of Pathology and Clinical Laboratories National Cancer Center Hospital East Kashiwa Japan
22 shared publications - Hideki Furuya
Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
21 shared publications - Tetsuro Taki
Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
21 shared publications - Hiroyoshi Nishikawa
Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan
14 shared publications - Masahiro Tsuboi
Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan
14 shared publications - Joji Samejima
Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan
13 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Outcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis
Onishi J, et al. J Gynecol Oncol. 2027 ;38:e7. https://doi.org/10.3802/jgo.2027.38.e7
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessOutcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis
Onishi J, et al. J Gynecol Oncol. 2027 ;38:e7. https://doi.org/10.3802/jgo.2027.38.e7
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 1. Correlation between tumor shrinkage and number of genetic variants. Correlation analysis of tumor shrinkage versus the number of gene mutations in the specimens obtained from (a) cohort 1 and (b) cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 1. Correlation between tumor shrinkage and number of genetic variants. Correlation analysis of tumor shrinkage versus the number of gene mutations in the specimens obtained from (a) cohort 1 and (b) cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 3. Progression-free survival. Kaplan-Meier estimates of progression-free survival in (a) cohort 1 and (b) cohort 2. Disease progression was reported for 2 patients in cohort 1 and 3 patients in cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 3. Progression-free survival. Kaplan-Meier estimates of progression-free survival in (a) cohort 1 and (b) cohort 2. Disease progression was reported for 2 patients in cohort 1 and 3 patients in cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 2. Correlation between tumor shrinkage and tumor mutational burden (TMB). Correlation analysis of tumor shrinkage versus TMB in (a) cohort 1 and (b) cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 2. Correlation between tumor shrinkage and tumor mutational burden (TMB). Correlation analysis of tumor shrinkage versus TMB in (a) cohort 1 and (b) cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 5. Baseline immune-cell infiltration according to BRCA1/2 mutation status. Baseline immune-cell infiltration was compared between pretreatment biopsy samples from patients with BRCA1-mutated and BRCA2-mutated tumors using immunohistochemistry. CD3+, CD4+, CD8+, FOXP3+, CD20+, and CD204+ cells, as well as tertiary lymphoid structures (TLSs), were quantified and compared between the two groups. No statistically significant differences were observed in any of the evaluated immune-cell populations or TLSs between BRCA1-and BRCA2-mutated tumors. P values are shown for each comparison.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 5. Baseline immune-cell infiltration according to BRCA1/2 mutation status. Baseline immune-cell infiltration was compared between pretreatment biopsy samples from patients with BRCA1-mutated and BRCA2-mutated tumors using immunohistochemistry. CD3+, CD4+, CD8+, FOXP3+, CD20+, and CD204+ cells, as well as tertiary lymphoid structures (TLSs), were quantified and compared between the two groups. No statistically significant differences were observed in any of the evaluated immune-cell populations or TLSs between BRCA1-and BRCA2-mutated tumors. P values are shown for each comparison.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 1. Representativeness of Study Participants.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 1. Representativeness of Study Participants.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 4. Compartment-specific immunohistochemical analysis of immune-cell infiltration before and after treatment. Quantification of immune-cell infiltration and tertiary lymphoid structures (TLSs) in paired baseline biopsy and posttreatment surgical specimens. a, b, Tumor-compartment infiltration of CD3+, CD4+, CD8+, FOXP3+, and CD20+ lymphocytes, CD204+ macrophages, and TLSs in a, Cohort 1 and b, Cohort 2. c, d, Stromal-compartment infiltration of CD4+, CD8+, and FOXP3+ cells in c, Cohort 1 and d, Cohort 2. e, f, CD4/CD8 and FOXP3/CD8 ratios in e, the tumor compartment and f, the stromal compartment. Comparisons were performed between pretreatment baseline samples and posttreatment surgical samples.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 4. Compartment-specific immunohistochemical analysis of immune-cell infiltration before and after treatment. Quantification of immune-cell infiltration and tertiary lymphoid structures (TLSs) in paired baseline biopsy and posttreatment surgical specimens. a, b, Tumor-compartment infiltration of CD3+, CD4+, CD8+, FOXP3+, and CD20+ lymphocytes, CD204+ macrophages, and TLSs in a, Cohort 1 and b, Cohort 2. c, d, Stromal-compartment infiltration of CD4+, CD8+, and FOXP3+ cells in c, Cohort 1 and d, Cohort 2. e, f, CD4/CD8 and FOXP3/CD8 ratios in e, the tumor compartment and f, the stromal compartment. Comparisons were performed between pretreatment baseline samples and posttreatment surgical samples.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 2. Chemotherapy response scores.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 2. Chemotherapy response scores.
- Open Access
- 26 September 2026
- Published by Elsevier in SSRN Electronic Journal
Temperature controlled limb cooling for the prevention of paclitaxel-induced peripheral neuropathy: a multicenter, double-blind, randomized controlled trial
Background: Chemotherapy-induced peripheral neuropathy (CIPN) impairs a patient’s quality of life; however, prevention strategies are lacking. This study evaluated whether limb-cooling with stable temperature control reduced CIPN in patients with breast cancer receiving weekly paclitaxel as perioperative treatment. Methods: This multicenter, double-blind, randomized controlled trial included patients with breast cancer scheduled to receive 12 weekly doses of paclitaxel as perioperative chemotherapy. Overall, 150 patients were randomly assigned to either the experimental (n = 75) or control (n = 75) groups and to limb-cooling therapy maintained at a constant temperature of either 13 (experimental) or 25 °C (control) during paclitaxel infusion. The primary endpoint was the proportion of patients who reported Patient Neurotoxicity Questionnaire (PNQ) ≥D in their limbs by the end of paclitaxel treatment or at the time of discontinuation. Results: Paclitaxel completion rates of ≥80% were 88.0% (experimental) and 93.3% (control). By the end of the treatment, the proportions of patients reporting PNQ ≥D were similar between the groups (13 vs. 25 °C, 33.3% vs. 29.3%, one-sided P = 0.76). The proportion was higher in the experimental group at 3 months after completion of paclitaxel treatment and among participants enrolled during the summer. No frostbite cases or other adverse events were reported. Conclusion: Although the primary endpoint was not met, limb-cooling therapy using a stable cooling device resulted in a lower proportion of patients with PNQ≥D than anticipated for controls. The device showed good adherence, a satisfactory safety profile, and may be suitable for clinical use. Trial Registration: jRCT2032210115
- 26 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTemperature controlled limb cooling for the prevention of paclitaxel-induced peripheral neuropathy: a multicenter, double-blind, randomized controlled trial
Background: Chemotherapy-induced peripheral neuropathy (CIPN) impairs a patient’s quality of life; however, prevention strategies are lacking. This study evaluated whether limb-cooling with stable temperature control reduced CIPN in patients with breast cancer receiving weekly paclitaxel as perioperative treatment. Methods: This multicenter, double-blind, randomized controlled trial included patients with breast cancer scheduled to receive 12 weekly doses of paclitaxel as perioperative chemotherapy. Overall, 150 patients were randomly assigned to either the experimental (n = 75) or control (n = 75) groups and to limb-cooling therapy maintained at a constant temperature of either 13 (experimental) or 25 °C (control) during paclitaxel infusion. The primary endpoint was the proportion of patients who reported Patient Neurotoxicity Questionnaire (PNQ) ≥D in their limbs by the end of paclitaxel treatment or at the time of discontinuation. Results: Paclitaxel completion rates of ≥80% were 88.0% (experimental) and 93.3% (control). By the end of the treatment, the proportions of patients reporting PNQ ≥D were similar between the groups (13 vs. 25 °C, 33.3% vs. 29.3%, one-sided P = 0.76). The proportion was higher in the experimental group at 3 months after completion of paclitaxel treatment and among participants enrolled during the summer. No frostbite cases or other adverse events were reported. Conclusion: Although the primary endpoint was not met, limb-cooling therapy using a stable cooling device resulted in a lower proportion of patients with PNQ≥D than anticipated for controls. The device showed good adherence, a satisfactory safety profile, and may be suitable for clinical use. Trial Registration: jRCT2032210115
- Open Access
- 24 September 2026
- Published by Elsevier in SSRN Electronic Journal
Lobectomy versus segmentectomy for centrally located, small-sized (≤ 2 cm), and radiologically solid-dominant non-small cell lung cancer: a phase III randomized controlled trial (UNLIMITED; JCOG2501)
BackgroundSegmentectomy has demonstrated favorable long-term outcomes compared with lobectomy in patients with small peripheral non-small cell lung cancer (NSCLC). However, whether similar benefits can be achieved in centrally located, small-sized, radiologically solid-dominant NSCLC remains uncertain. This study aims to confirm the non-inferiority of segmentectomy to lobectomy within this setting.MethodsJCOG2501 is a multi-institutional, open-label, phase III, randomized controlled trial designed to confirm the non-inferiority of segmentectomy to lobectomy in patients with centrally located (within the inner two-thirds of the lung field), small-sized (maximum tumor diameter ≤2 cm), radiologically solid-dominant (consolidation-to-tumor ratio, >0.5 to ≤1) NSCLC. Eligible patients are aged 18–85 years with an Eastern Cooperative Oncology Group performance status of 0–1 and adequate pulmonary function. A two-step registration system is adopted, with preoperative and intraoperative confirmation of patient eligibility. Following confirmation of eligibility at the second registration, patients are randomized 1:1 to either the lobectomy or segmentectomy arm. In both arms, systematic or lobe-specific lymph node dissection is mandatory, and nodal sampling alone is prohibited. The primary endpoint is overall survival, analyzed in all randomized patients. Assuming a non-inferiority margin of 6.5% for 5-year overall survival, 490 patients are required to achieve 70% power with a one-sided α = 5%. The planned sample size is 500 patients at the second registration. JCOG2501 was initiated in February 2026 and is registered with the Japan Registry of Clinical Trials (jRCT1030250727).ConclusionsJCOG2501 will clarify the role of segmentectomy in centrally located small-sized NSCLC and inform future surgical standards.
- 24 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLobectomy versus segmentectomy for centrally located, small-sized (≤ 2 cm), and radiologically solid-dominant non-small cell lung cancer: a phase III randomized controlled trial (UNLIMITED; JCOG2501)
BackgroundSegmentectomy has demonstrated favorable long-term outcomes compared with lobectomy in patients with small peripheral non-small cell lung cancer (NSCLC). However, whether similar benefits can be achieved in centrally located, small-sized, radiologically solid-dominant NSCLC remains uncertain. This study aims to confirm the non-inferiority of segmentectomy to lobectomy within this setting.MethodsJCOG2501 is a multi-institutional, open-label, phase III, randomized controlled trial designed to confirm the non-inferiority of segmentectomy to lobectomy in patients with centrally located (within the inner two-thirds of the lung field), small-sized (maximum tumor diameter ≤2 cm), radiologically solid-dominant (consolidation-to-tumor ratio, >0.5 to ≤1) NSCLC. Eligible patients are aged 18–85 years with an Eastern Cooperative Oncology Group performance status of 0–1 and adequate pulmonary function. A two-step registration system is adopted, with preoperative and intraoperative confirmation of patient eligibility. Following confirmation of eligibility at the second registration, patients are randomized 1:1 to either the lobectomy or segmentectomy arm. In both arms, systematic or lobe-specific lymph node dissection is mandatory, and nodal sampling alone is prohibited. The primary endpoint is overall survival, analyzed in all randomized patients. Assuming a non-inferiority margin of 6.5% for 5-year overall survival, 490 patients are required to achieve 70% power with a one-sided α = 5%. The planned sample size is 500 patients at the second registration. JCOG2501 was initiated in February 2026 and is registered with the Japan Registry of Clinical Trials (jRCT1030250727).ConclusionsJCOG2501 will clarify the role of segmentectomy in centrally located small-sized NSCLC and inform future surgical standards.